FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jörg Kotzerke

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Phenomena

Beta Particles

Devices

Radiometry

Co-author Network

Publications

TOP 3
Alexander Storch; Jörg van den Hoff; Martin Wolz; Uta Schwanebeck; Bettina Beuthien-Baumann; Xina Grählert; Birgit Herting; Jörg Kotzerke; Matthias Löhle; L Oehme; Maria Perick; Heinz Reichmann
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Ivan Platzek; Manuel Popp; Georg Schramm; Bettina Beuthien-Baumann; Jörg Kotzerke; Jens Langner; Michael Laniado; Rainer Ordemann; Jörg van den Hoff
PET/MR for therapy response evaluation in malignant lymphoma: initial experience.
Georg Schramm; Jörg Steinbach; Bettina Beuthien-Baumann; Frank Hofheinz; Jörg Kotzerke; Jens Langner; Jan Petr; Ivan Platzek; Jörg van den Hoff
Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jörg Kotzerke (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alexander Storch; Jörg van den Hoff; Martin Wolz; Uta Schwanebeck; Bettina Beuthien-Baumann; Xina Grählert; Birgit Herting; Jörg Kotzerke; Matthias Löhle; L Oehme; Maria Perick; Heinz Reichmann
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Neurology 2013;80(19):1754-61.
2013: Ivan Platzek; Manuel Popp; Georg Schramm; Bettina Beuthien-Baumann; Jörg Kotzerke; Jens Langner; Michael Laniado; Rainer Ordemann; Jörg van den Hoff
PET/MR for therapy response evaluation in malignant lymphoma: initial experience.
Magma (New York, N.Y.) 2013;26(1):49-55.
2013: Georg Schramm; Jörg Steinbach; Bettina Beuthien-Baumann; Frank Hofheinz; Jörg Kotzerke; Jens Langner; Jan Petr; Ivan Platzek; Jörg van den Hoff
Quantitative accuracy of attenuation correction in the Philips Ingenuity TF whole-body PET/MR system: a direct comparison with transmission-based attenuation correction.
Magma (New York, N.Y.) 2013;26(1):115-26.
2013: H Hartmann; Michael Andreeff; R Freudenberg; Jörg Kotzerke
[Determination of radioactivity by smartphones].
Nuklearmedizin. Nuclear medicine 2013;52(2):64-70.
2013: Claudia Brogsitter; Eva Kämmerer; Annette Stein; Gerd Wunderlich; Klaus Zöphel; Jörg Kotzerke
Comparison between F-18 fluorodeoxyglucose and Ga-68 DOTATOC in metastasized melanoma.
Nuclear medicine communications 2013;34(1):47-9.
2013: Ivan Platzek; Matthias Schneider; Georg Schramm; Bettina Beuthien-Baumann; Volker Gudziol; Jörg Kotzerke; Jens Langner; Michael Laniado; Jörg van den Hoff
PET/MRI in head and neck cancer: initial experience.
European journal of nuclear medicine and molecular imaging 2013;40(1):6-11.
2012: Robert Freudenberg; Roswitha Runge; Maria Wendisch; Gerd Wunderlich; Jörg Kotzerke
Reduction in clonogenic survival of sodium-iodide symporter (NIS)-positive cells following intracellular uptake of (99m)Tc versus (188)Re.
International journal of radiation biology 2012;88(12):991-7.
2012: Daniel Zips; Klaus Zöphel; Nasreddin D Abolmaali; Andrij Abramyuk; Steffen Appold; Robert Haase; Jörg Kotzerke; Rosalind Perrin; Jörg Steinbach; Michael Baumann
Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;105(1):21-8.
2012: Bettina Beuthien-Baumann; Michael Laniado; Ingrid Lauterbach; Ivan Platzek; Georg Schramm; Jörg van den Hoff; Klaus Zöphel; Jörg Kotzerke
Improved anatomic visualization of a glomus caroticum tumour within the carotic bifurcation with combined 68Ga-DOTATATE PET/MRI.
European journal of nuclear medicine and molecular imaging 2012;39(6):1087-8.
2012: Robert Freudenberg; Jörg Kotzerke
Dosimetry of 99mTc-HMPAO in mesenchymal stem cells.
Nuclear medicine and biology 2012;39(3):443; author reply 445-6.
2012: Claudia Brogsitter; Jörg Kotzerke
Radioisotope-antibody conjugates selectively target bone marrow prior to stem cell therapy.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2012;102(2):321.
2012: Jörg Kotzerke; L A Kunz-Schughart; G J Meyer; L Oehme; Roswitha Runge; M Wendisch; R Freudenberg; Gerd Wunderlich
Sodium-iodide symporter positive cells after intracellular uptake of (99m)Tc versus α-emitter 211At. Reduction of clonogenic survival and characterization of DNA damage.
Nuklearmedizin. Nuclear medicine 2012;51(5):170-8.
2012: Bettina Beuthien-Baumann; G Holl; Vjera Holthoff; Jörg Kotzerke; P Mäding; Beate Pawelke; Ralf Bergmann; Rüdiger von Kummer; Jörg van den Hoff
18F-labelled CCR1-receptor antagonist is not suitable for imaging of Alzheimer's disease.
Nuklearmedizin. Nuclear medicine 2012;51(6):239-43.
2012: Frank Hofheinz; Jörg Kotzerke; Jens Langner; L Oehme; Jan Petr; Jörg Steinbach; Bettina Beuthien-Baumann; Jörg van den Hoff
A method for model-free partial volume correction in oncological PET.
EJNMMI research 2012;2(1):16.
2012: Gerd Wunderlich; D Aurich; R Freudenberg; Roswitha Runge; M Wendisch; Jörg Kotzerke
Preincubation with Sn-complexes causes intensive intracellular retention of (99m)Tc in thyroid cells in vitro.
Nuklearmedizin. Nuclear medicine 2012;51(5):179-85.
2012: M Andreeff; J Claussnitzer; R Freudenberg; L Oehme; Jörg Kotzerke
[Measurement of ocular lens ionizing radiation exposure after radioiodine therapy].
Nuklearmedizin. Nuclear medicine 2012;51(3):79-83.
2012: F Hofheinz; Jörg Kotzerke; L Oehme; C Pötzsch; J Steinbach; Bettina Beuthien-Baumann; J van den Hoff
Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets.
Nuklearmedizin. Nuclear medicine 2012;51(1):9-16.
2011: Knut Liepe; L Oehme; Gerd Wunderlich; Michael Andreeff; Wolfgang Dörr; Diana Faulhaber; Michael Haase; Roland Jung; Jörg Kotzerke
Radiation pneumopathy in the rat after intravenous application of (188)Re-labeled microspheres.
International journal of radiation oncology, biology, physics 2011;81(2):529-36.
2011: L Oehme; Maria Perick; Heinz Reichmann; Alexander Storch; Jörg van den Hoff; Martin Wolz; Bettina Beuthien-Baumann; Birgit Herting; Jens Langner; Matthias Löhle; Jörg Kotzerke
Comparison of dopamine turnover, dopamine influx constant and activity ratio of striatum and occipital brain with ¹⁸F-dopa brain PET in normal controls and patients with Parkinson's disease.
European journal of nuclear medicine and molecular imaging 2011;38(8):1550-9.
2011: Holger Hartmann; L Oehme; Jörg Kotzerke
86Y-DOTATOC uptake in red marrow is not routinely visible.
European journal of nuclear medicine and molecular imaging 2011;38(7):1384-5.
2011: Maria Hentschel; Steffen Appold; Andreas Schreiber; Nasreddin D Abolmaali; Andrij Abramyuk; Wolfgang Dörr; Jörg Kotzerke; Michael Baumann; Klaus Zöphel
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer.
European journal of nuclear medicine and molecular imaging 2011;38(7):1203-11.
2011: Klaus Zöphel; Jörg Kotzerke; Carl-Martin Kirsch
Correspondence (letter to the editor): Nuclear medicine offers therapeutic options for multiple bone metastases.
Deutsches Ärzteblatt international 2011;108(20):357.
2011: Claudia Brogsitter; Diana Faulhaber; Jörg Kotzerke
Intraarterial treatment of GEP NET: (68)Ga-DOTATOC SUV cannot predict (90)Y-DOTATOC uptake.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(7):2065.
2010: Cindy Kahmann; Gerd Wunderlich; Robert Freudenberg; Klaus Zöphel; L Oehme; Jörg Kotzerke
Radioprotection of thyroid cells mediated by methimazole.
International journal of radiation biology 2010;86(10):811-6.
2010: Wolfgang Luboldt; Teresa Volker; Bärbel Wiedemann; Klaus Zöphel; Ursula Wehrmann; Arne Koch; Todd Toussaint; Nasreddin Abolmaali; Markus Middendorp; Daniela Aust; Jörg Kotzerke; Frank Grünwald; Thomas J Vogl; Hans-Joachim Luboldt
Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off.
European radiology 2010;20(9):2274-85.
2010: Anett Lauter; Annette Strumpf; Uwe Platzbecker; Johannes Schetelig; Martin Wermke; Jörgen Radke; Alexander Kiani; Gerd Wunderlich; Christian Thiede; Gerhard Ehninger; Jörg Kotzerke; Martin Bornhäuser
188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning and in-vivo T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation.
British journal of haematology 2010;148(6):910-7.
2010: Jörg Kotzerke; L Oehme
[Biological aspects of radiation in nuclear medicine].
Nuklearmedizin. Nuclear medicine 2010;49 Suppl 1():S5-S10.
2010: Jörg Kotzerke; Michael Andreeff; Gerd Wunderlich; P Wiggermann; Klaus Zöphel
[Ventilation-perfusion-lungscintigraphy using PET and 68Ga-labeled radiopharmaceuticals].
Nuklearmedizin. Nuclear medicine 2010;49(6):203-8.
2010: Axel Heidenreich; Peter Albers; Johannes Classen; Markus Graefen; Jürgen Gschwend; Jörg Kotzerke; Susanne Krege; Jens Lehmann; Detlef Rohde; Heinz Schmidberger; Michael Uder; Hajo Zeeb
Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society.
Urologia internationalis 2010;85(1):1-10.
2010: M Wendisch; R Freudenberg; J Drechsel; Roswitha Runge; Gerd Wunderlich; Jörg Kotzerke
[99mTc reduces clonogenic survival after intracellular uptake in NIS-positive cells in vitro more than 131I].
Nuklearmedizin. Nuclear medicine 2010;49(4):154-60.
2010: M Popp; A Strumpf; Klaus Zöphel; Christian Stroszczynski; Jörg Kotzerke
Intraarterial 131I-MIBG therapy of neuroendocrine tumors with liver metastases.
Nuklearmedizin. Nuclear medicine 2010;49(1):N2-3.
2010: Jörg Kotzerke; L Oehme; O Lindner; D Hellwig
[Positron emission tomography 2008 in Germany - results of the query and current status].
Nuklearmedizin. Nuclear medicine 2010;49(2):58-64.
2010: Jörg Kotzerke; M Dietlein; F Grünwald; A Bockisch
[PET and diagnostic technology evaluation in a global clinical process. DGN's point of view].
Nuklearmedizin. Nuclear medicine 2010;49(1):6-12.
2010: Gerd Wunderlich; P Herrling; A Zürn; P Anders; Jörg Kotzerke
[Chromatographic determination of radiochemical purity - replacement of ITLC SG].
Nuklearmedizin. Nuclear medicine 2010;49(2):73-7.
2010: Jörg Kotzerke; Michael Andreeff; Gerd Wunderlich
PET aerosol lung scintigraphy using Galligas.
European journal of nuclear medicine and molecular imaging 2010;37(1):175-7.
2010: Klaus Zöphel; D Roggenbuck; Philipp von Landenberg; Gerd Wunderlich; Thomas Grüning; Jörg Kotzerke; K J Lackner; B Rees Smith
TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2010;42(1):65-9.
2010: Manuel Popp; Annette Strumpf; Klaus Zöphel; Christian Stroszczynski; Jörg Kotzerke
Increased uptake of (131)I-MIBG after intra-arterial application in liver metastases of a neuroendocrine tumor.
European journal of nuclear medicine and molecular imaging 2010;37(1):180.
2009: Knut Liepe; Hans Heiner Geidel; Ralf Bergmann; Michael Haase; Roswitha Runge; Jörg Kotzerke
Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer.
Nuclear medicine communications 2009;30(9):693-9.
2009: Wolfgang Luboldt; Jörg Pinkert; Christian Matzky; Gerd Wunderlich; Jörg Kotzerke
Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics.
Current drug delivery 2009;6(3):255-60.
2009: Klaus Zöphel; Gerd Wunderlich; Jörg Kotzerke; Philipp von Landenberg; Dirk Roggenbuck
M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays.
Clinica chimica acta; international journal of clinical chemistry 2009;403(1-2):266.
2009: Liane Oehme; Jörg Kotzerke
Radiobiological considerations for radioembolization with 188Re-microspheres.
European journal of nuclear medicine and molecular imaging 2009;36(2):322-5.
2009: Andreas Bockisch; Jörg Kotzerke
[Nuclear medicine].
Nuklearmedizin. Nuclear medicine 2009;48(6):N61-3.
2009: Michael Andreeff; D Sommer; R Freudenberg; U Reichelt; J Henniger; Jörg Kotzerke
[BeO-OSL detectors for dose measurements in cell cultures].
Nuklearmedizin. Nuclear medicine 2009;48(6):227-32.
2009: Roswitha Runge; M Wendisch; Gerd Wunderlich; R Freudenberg; Jörg Kotzerke
[DNA damage in lymphocytes after irradiation with 211At and 188Re].
Nuklearmedizin. Nuclear medicine 2009;48(6):221-6.
2009: M Wendisch; J Drechsel; R Freudenberg; Roswitha Runge; Gerd Wunderlich; Jörg Kotzerke
[Cellular damage in vitro].
Nuklearmedizin. Nuclear medicine 2009;48(5):208-14.
2009: Robert Freudenberg; Michael Andreeff; L Oehme; Jörg Kotzerke
[Dosimetry of cell-monolayers in multiwell plates].
Nuklearmedizin. Nuclear medicine 2009;48(3):120-6.
2008: Gerd Wunderlich; H Hartmann; M Andreeff; Jörg Kotzerke
A semi-automated system for concentration of rhenium-188 for radiopharmaceutical applications.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2008;66(12):1876-80.
2008: Lidiya Zuderman; Knut Liepe; Klaus Zöphel; Michael Andreeff; Jörg Kotzerke; Wolfgang Luboldt
Radiosynoviorthesis (RSO): influencing factors and therapy monitoring.
Annals of nuclear medicine 2008;22(9):735-41.
2008: Klaus Zöphel; Annette Strumpf; Gerd Wunderlich; L Oehme; Graeme Eisenhofer; Jörg Kotzerke
Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy.
Clinical nuclear medicine 2008;33(10):690-1.
2008: Klaus Zöphel; Jörg Kotzerke
High intraindividual variability of global myocardial 18F-FDG uptake over time.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(9):1570; author reply 1570-1.
2008: Charles Gillham; Daniel Zips; Falk Pönisch; Carsten Evers; Wolfgang Enghardt; Nasreddin D Abolmaali; Klaus Zöphel; Steffen Appold; Tobias Hoelscher; Jörg Steinbach; Jörg Kotzerke; Thomas Herrmann; Michael Baumann
Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;88(3):335-41.
2008: Klaus Zöphel; Thomas Grüning; Dirk Roggenbuck; Gerd Wunderlich; Jörg Kotzerke
On specificity of 2nd generation TSH receptor autoantibody measurements.
Clinical laboratory 2008;54(7-8):243-9.
2008: L Oehme; W Dörr; P Wust; Jörg Kotzerke
[Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry].
Nuklearmedizin. Nuclear medicine 2008;47(5):205-9.
2008: Horst Alheit; L Oehme; Cornelia Winkler; F Füchtner; A Hoepping; J Grabowski; Jörg Kotzerke; B Beuthien-Baumann
Radiation treatment planning in brain tumours: potential impact of 3-O-methyl-6-[(18)F]fluoro-L-DOPA and PET.
Nuklearmedizin. Nuclear medicine 2008;47(5):200-4.
2008: Klaus Zöphel; Philipp von Landenberg; Dirk Roggenbuck; Gerd Wunderlich; Jörg Kotzerke; Karl J Lackner
Are porcine and human TSH receptor antibody measurements comparable?
Clinical laboratory 2008;54(1-2):1-8.
2007: Knut Liepe; Claudia Brogsitter; Johannes Leonhard; Gerd Wunderlich; Reiner Hliscs; Jörg Pinkert; Gunnar Folprecht; Jörg Kotzerke
Feasibility of high activity rhenium-188-microsphere in hepatic radioembolization.
Japanese journal of clinical oncology 2007;37(12):942-50.
2007: Christian Hoelzel; Claus Gillitzer; Jörg Kotzerke
The floating Meckel.
Clinical nuclear medicine 2007;32(10):810-1.
2007: Bettina Beuthien-Baumann; A Strumpf; J Zessin; Jan Bredow; Jörg Kotzerke
Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
European journal of nuclear medicine and molecular imaging 2007;34(10):1604-9.
2007: Knut Liepe; Jörg Kotzerke
A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
Nuclear medicine communications 2007;28(8):623-30.
2007: Klaus Zöphel; C Hölzel; M Dawel; Tobias Hoelscher; C Evers; Jörg Kotzerke
PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy.
European journal of nuclear medicine and molecular imaging 2007;34(8):1322-3.
2007: Christina Schütze; Ralf Bergmann; Ala Yaromina; Franziska Hessel; Jörg Kotzerke; Jörg Steinbach; Michael Baumann; Bettina Beuthien-Baumann
Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;83(3):311-5.
2007: Jörg Kotzerke; Clemens Linné; Matthias Meinhardt; Jörg Steinbach; M Wirth; Gustavo B Baretton; Nasreddin D Abolmaali; Bettina Beuthien-Baumann
[1-(11)C]acetate uptake is not increased in renal cell carcinoma.
European journal of nuclear medicine and molecular imaging 2007;34(6):884-8.
2007: Jörg Kotzerke; Klaus Zöphel; Georg Salomon; Markus Graefen; Axel Heidenreich
[Pro and contra: 11C choline PET in diagnosis of prostate cancer].
Aktuelle Urologie 2007;38(3):189-94.
2007: Sepp Seifert; C Jentschel; Ralf Bergmann; Hans-Jürgen Pietzsch; Gerd Wunderlich; Jörg Kotzerke; Jörg Steinbach
Very stable 188Re-S4 chelates for labelling biomolecules: preparation with highly concentrated perrhenate eluates.
Nuklearmedizin. Nuclear medicine 2007;46(5):181-4.
2007: Susanne Martina Eschmann; Godehard Friedel; Frank Paulsen; Matthias Reimold; Thomas Hehr; Jutta Scheiderbauer; Wilfried Budach; Jörg Kotzerke; Roland Bares
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
European journal of nuclear medicine and molecular imaging 2007;34(1):54-9.
2006: Jochen Wöhrle; Bernd J Krause; Thorsten Nusser; Felix Mottaghy; Thomas Habig; Matthias Kochs; Jörg Kotzerke; Sven N Reske; Vinzenz Hombach; Martin Höher
Intracoronary beta-brachytherapy using a rhenium-188 filled balloon catheter in restenotic lesions of native coronary arteries and venous bypass grafts.
European journal of nuclear medicine and molecular imaging 2006;33(11):1314-20.
2006: M Bamberg; V Diehl; T Herrmann; H Jürgens; J R Siewert; Jörg Kotzerke
[Positron emission tomography (PET) in oncology: a part of medical therapeutic expertise].
Deutsche medizinische Wochenschrift (1946) 2006;131(10):512-5.
2006: Klaus Zöphel; Gerd Wunderlich; Jörg Kotzerke
A highly sensitive thyroglobulin assay has superior diagnostic sensitivity for recurrence of differentiated thyroid cancer in patients undergoing TSH suppression.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(3):552-3; author reply 553.
2006: Thorsten Zenz; Richard F Schlenk; Gerhard Glatting; Bernd Neumaier; Norbert M Blumstein; Inga Buchmann; Stephanie von Harsdorf; Mark Ringhoffer; Markus Wiesneth; Frieder Keller; Jörg Kotzerke; Erwin M Röttinger; Stephan Stilgenbauer; Hartmut Döhner; Sven N Reske; Donald Bunjes
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(2):278-86.
2006: Klaus Zöphel; Gerd Wunderlich; Jörg Kotzerke
Should we really determine a reference population for the definition of thyroid-stimulating hormone reference interval?
Clinical chemistry 2006;52(2):329-30.
2005: Claudia Brogsitter; Jörg Pinkert; Jan Bredow; Thomas Kittner; Jörg Kotzerke
Enhanced tumor uptake in neuroendocrine tumors after intraarterial application of 131I-MIBG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(12):2112-6.
2005: Jörg Kotzerke; D Bunjes; David A Scheinberg
Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
Bone marrow transplantation 2005;36(12):1021-6.
2005: Knut Liepe; Roswitha Runge; Jörg Kotzerke
Systemic radionuclide therapy in pain palliation.
The American journal of hospice & palliative care 2005;22(6):457-64.
2005: Mark Ringhoffer; Norbert M Blumstein; Bernd Neumaier; Gerhard Glatting; Stephanie von Harsdorf; Inga Buchmann; Markus Wiesneth; Jörg Kotzerke; Thorsten Zenz; Andreas K Buck; Peter Schauwecker; Stephan Stilgenbauer; Hartmut Döhner; Sven N Reske; Donald Bunjes
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
British journal of haematology 2005;130(4):604-13.
2005: Knut Liepe; Jörg Kotzerke; Bieke Lambert
Advantage of 188Re-radiopharmaceuticals in hepatocellular cancer and liver metastases.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2005;46(8):1407-8; author reply 1407-8.
2005: Knut Liepe; Michael Andreeff; Gerd Wunderlich; Jörg Kotzerke
Radiation protection in radiosynovectomy of the knee.
Health physics 2005;89(2):151-4.
2005: Gerd Wunderlich; Antje Drews; Jörg Kotzerke
A kit for labeling of [188Re] human serum albumin microspheres for therapeutic use in nuclear medicine.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2005;62(6):915-8.
2005: Gerd Wunderlich; Jörg Pinkert; Michael Stintz; Jörg Kotzerke
Labeling and biodistribution of different particle materials for radioembolization therapy with 188Re.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2005;62(5):745-50.
2005: Klaus Zöphel; Gerd Wunderlich; Thomas Grüning; Rainer Koch; H Döge; Jörg Kotzerke
[Where does subclinical hypothyroidism start? Implications for the definition of the upper reference limit for thyroid stimulating hormone].
Nuklearmedizin. Nuclear medicine 2005;44(2):56-61.
2005: Knut Liepe; H Geidel; M Haase; Oliver Hakenberg; Roswitha Runge; Jörg Kotzerke
New model for the induction of osteoblastic bone metastases in rat.
Anticancer research 2005;25(2A):1067-73.
2005: Knut Liepe; Roswitha Runge; Jörg Kotzerke
The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.
Journal of cancer research and clinical oncology 2005;131(1):60-6.
2004: Holger Schirrmeister; Jörg Kotzerke; Florian Vogl; Andreas Buck; Norbert Czech; Karin Koretz; Gisela Helm; Rolf Kreienberg; Thorsten Kühn
Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients.
Cancer biotherapy & radiopharmaceuticals 2004;19(6):784-90.
2004: Ralf Bergmann; Jens Pietzsch; Frank Fuechtner; Beate Pawelke; Bettina Beuthien-Baumann; Bernd Johannsen; Jörg Kotzerke
3-O-methyl-6-18F-fluoro-L-dopa, a new tumor imaging agent: investigation of transport mechanism in vitro.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2004;45(12):2116-22.
2004: Paul Bühler; Uwe Just; Edmund Will; Jörg Kotzerke; Jörg van den Hoff
An accurate method for correction of head movement in PET.
IEEE transactions on medical imaging 2004;23(9):1176-85.
2004: Claudia Brogsitter; A Wonsak; K Würl; Jörg Kotzerke
Peritoneal strumosis.
European journal of nuclear medicine and molecular imaging 2004;31(7):1057.
2004: Klaus Zöphel; Jörg Kotzerke
Is 11C-choline the most appropriate tracer for prostate cancer? Against.
European journal of nuclear medicine and molecular imaging 2004;31(5):756-9.
2004: Jan Bredow; M Kretzschmar; Gerd Wunderlich; W Dörr; T Pohl; Wolf-Gunter Franke; Jörg Kotzerke
[Therapy of malignant ascites in vivo by 211At-labelled microspheres].
Nuklearmedizin. Nuclear medicine 2004;43(2):63-8.
2004: Alexander Babiak; Anke-Mira Schumm; Christoph Wangler; Marios Loukas; Jianbo Wu; Saskia Dombrowski; Christiane Matuschek; Jörg Kotzerke; Christoph Dehio; Johannes Waltenberger
Coordinated activation of VEGFR-1 and VEGFR-2 is a potent arteriogenic stimulus leading to enhancement of regional perfusion.
Cardiovascular research 2004;61(4):789-95.
2004: Ralph Naumann; Bettina Beuthien-Baumann; A Reiss; J Schulze; Annette Hänel; Jan Bredow; G Kühnel; Joachim Kropp; Mathias Hänel; Michael Laniado; Jörg Kotzerke; Gerhard Ehninger
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma.
British journal of cancer 2004;90(3):620-5.
2004: Gerd Wunderlich; Thomas Grüning; Bernd-R Paulke; Antje Lieske; Jörg Kotzerke
99mTc labelled model drug carriers - labeling, stability and organ distribution in rats.
Nuclear medicine and biology 2004;31(1):87-92.
2003: Andreas K Buck; Gisela Halter; Holger Schirrmeister; Jörg Kotzerke; Imke Wurziger; Gerhard Glatting; Torsten Mattfeldt; Bernd Neumaier; Sven N Reske; Martin Hetzel
Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(9):1426-31.
2003: Claudia Friesen; Annelie Lubatschofski; Jörg Kotzerke; Inga Buchmann; Sven N Reske; Klaus-Michael Debatin
Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells.
European journal of nuclear medicine and molecular imaging 2003;30(9):1251-61.
2003: Knut Liepe; Joachim Kropp; Roswitha Runge; Jörg Kotzerke
Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases.
British journal of cancer 2003;89(4):625-9.
2003: Bettina Beuthien-Baumann; Jan Bredow; W Burchert; Frank Füchtner; Ralf Bergmann; Horst Alheit; Gilfe Reiss; Reiner Hliscs; Ralf Steinmeier; Wolf-Gunter Franke; Bernd Johannsen; Jörg Kotzerke
3-O-methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging.
European journal of nuclear medicine and molecular imaging 2003;30(7):1004-8.
2003: Martin Höher; Jochen Wöhrle; Markus Wohlfrom; Joachim Kamenz; Thorsten Nusser; Olaf Grebe; Hartmut Hanke; Matthias Kochs; Sven N Reske; Vinzenz Hombach; Jörg Kotzerke
Intracoronary beta-irradiation with a rhenium-188-filled balloon catheter: a randomized trial in patients with de novo and restenotic lesions.
Circulation 2003;107(24):3022-7.
2003: Inga Buchmann; Andreas T J Vogg; Gerhard Glatting; Stefan Schultheiss; Peter Möller; Frank Leithäuser; Michael Schulte; Wilfried Gfrörer; Jörg Kotzerke; Sven N Reske
[18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
Cancer biotherapy & radiopharmaceuticals 2003;18(3):327-37.
2003: Knut Liepe; Michael Andreeff; J Mielcarek; I Barth; Gerd Wunderlich; Joachim Kropp; Jörg Kotzerke
[Beta-radiation exposure at the finger tips during the radionuclide synovectomy].
Nuklearmedizin. Nuclear medicine 2003;42(3):104-8.
2003: Inga Buchmann; Thomas Kull; Gerhard Glatting; Donald Bunjes; Geoffrey Hale; Jörg Kotzerke; Dirk Rattat; Hartmut Dohner; Sven N Reske
A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy.
European journal of nuclear medicine and molecular imaging 2003;30(5):667-73.
2003: Jörg Kotzerke; Bjoern G Volkmer; Gerhard Glatting; J van den Hoff; Juergen E Gschwend; PM Messer; Sven N Reske; Bernd Neumaier
Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer.
Nuklearmedizin. Nuclear medicine 2003;42(1):25-30.
2003: Klaus Zöphel; Gerd Wunderlich; C Kopprasch; Rainer Koch; Wolf-Gunter Franke; Jörg Kotzerke
[Predictive value of thyrotropin receptor antibodies using the second generation TRAb human assay after radioiodine treatment in Graves' disease].
Nuklearmedizin. Nuclear medicine 2003;42(2):63-70.
2002: Jörg Kotzerke; Bjoern G Volkmer; Bernd Neumaier; Juergen E Gschwend; Richard E Hautmann; Sven N Reske
Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.
European journal of nuclear medicine and molecular imaging 2002;29(10):1380-4.
2002: Andreas Buck; Holger Schirrmeister; Thorsten Kühn; Changxian Shen; Thomas Kalker; Jörg Kotzerke; Anja Dankerl; Gerhard Glatting; Sven N Reske; Torsten Mattfeldt
FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
European journal of nuclear medicine and molecular imaging 2002;29(10):1317-23.
2002: Jörg Kotzerke; Hartmut Hanke; Martin Höher
Interventional nuclear medicine in the prevention of restenosis following angioplasty.
Nuclear medicine communications 2002;23(9):843-5.
2002: Ernst R Kuse; Jörg Kotzerke; Silke Müller; Björn Nashan; Rainer Lück; Karsten Jaeger
Hepatic reticuloendothelial function during parenteral nutrition including an MCT/LCT or LCT emulsion after liver transplantation - a double-blind study.
Transplant international : official journal of the European Society for Organ Transplantation 2002;15(6):272-7.
2002: Sabine Fenchel; Dieter Grab; Karin Nuessle; Jörg Kotzerke; Andrea Rieber; Rolf Kreienberg; Hans-Juergen Brambs; Sven N Reske
Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings.
Radiology 2002;223(3):780-8.
2002: Inga Buchmann; Donald Bunjes; Jörg Kotzerke; Hans Martin; Gerhard Glatting; Ulrike Seitz; Dirk Rattat; Andreas Buck; Hartmut Döhner; Sven N Reske
Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
Cancer biotherapy & radiopharmaceuticals 2002;17(2):151-63.
2002: Jörg Kotzerke; Juergen E Gschwend; Bernd Neumaier
PET for prostate cancer imaging: still a quandary or the ultimate solution?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2002;43(2):200-2.
2001: Donald Bunjes; Inga Buchmann; C Duncker; Ulrike Seitz; Jörg Kotzerke; Markus Wiesneth; Dagmar Dohr; Martin Stefanic; Andreas Buck; Stephanie von Harsdorf; Gerhard Glatting; Wolfgang Grimminger; T Karakas; Gerd Munzert; Hartmut Döhner; Lothar Bergmann; Sven N Reske
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Blood 2001;98(3):565-72.
2001: Sven N Reske; Donald Bunjes; Inga Buchmann; Ulrike Seitz; Gerhard Glatting; Bernd Neumaier; Jörg Kotzerke; Andreas Buck; H Martin; Hartmut Döhner; Lothar Bergmann
Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation.
European journal of nuclear medicine 2001;28(7):807-15.
2001: Andreas C Buck; Holger Schirrmeister; CA Guhlmann; CG Diederichs; Changxian Shen; Inga Buchmann; Jörg Kotzerke; D Birk; Torsten Mattfeldt; Sven N Reske
Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2001;42(5):721-5.
2001: Jörg Kotzerke; Gerhard Glatting; J van den Hoff; Martin Höher; Bernd Neumaier; Jochen Wöhrle; Sven N Reske
Validation of myocardial blood flow estimation with nitrogen-13 ammonia PET by the argon inert gas technique in humans.
European journal of nuclear medicine 2001;28(3):340-5.
2001: Inga Buchmann; Michael Reinhardt; K Elsner; Donald Bunjes; Carsten Altehoefer; J Finke; E Moser; Gerhard Glatting; Jörg Kotzerke; CA Guhlmann; Holger Schirrmeister; Sven N Reske
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial.
Cancer 2001;91(5):889-99.
2001: Markus Wohlfrom; Jörg Kotzerke; Joachim Kamenz; M Eble; B Hess; Jochen Wöhrle; Sven N Reske; Vinzenz Hombach; Hartmut Hanke; Martin Höher
Endovascular irradiation with the liquid beta-emitter Rhenium-188 to reduce restenosis after experimental wall injury.
Cardiovascular research 2001;49(1):169-76.
2000: Michael Schulte; D Brecht-Krauss; B Heymer; Albrecht Guhlmann; Erich Hartwig; Michael R Sarkar; CG Diederichs; Alexandra von Baer; Jörg Kotzerke; Sven N Reske
Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(10):1695-701.
2000: Jörg Kotzerke; J Prang; Bernd Neumaier; Bjoern G Volkmer; Albrecht Guhlmann; Klaus Kleinschmidt; Richard Hautmann; Sven N Reske
Experience with carbon-11 choline positron emission tomography in prostate carcinoma.
European journal of nuclear medicine 2000;27(9):1415-9.
2000: Jörg Kotzerke; R Gertler; Inga Buchmann; Regine Baur; Vinzenz Hombach; S Norbert Reske; Rainer Voisard
Different radiosensitivity of smooth muscle cells and endothelial cells in vitro as demonstrated by irradiation from a Re-188 filled balloon catheter.
Atherosclerosis 2000;152(1):35-42.
2000: Martin Höher; Jochen Wöhrle; Markus Wohlfrom; Hartmut Hanke; Rainer Voisard; HH Osterhues; Matthias Kochs; Sven N Reske; Vinzenz Hombach; Jörg Kotzerke
Intracoronary beta-irradiation with a liquid (188)re-filled balloon: six-month results from a clinical safety and feasibility study.
Circulation 2000;101(20):2355-60.
2000: Jörg Kotzerke; Gerhard Glatting; Ulrike Seitz; M Rentschler; Bernd Neumaier; Donald Bunjes; C Duncker; Dagmar Dohr; Lothar Bergmann; Sven N Reske
Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2000;41(3):531-7.
2000: Jörg Kotzerke; Hartmut Hanke; Martin Höher
Endovascular brachytherapy for the prevention of restenosis after angioplasty.
European journal of nuclear medicine 2000;27(2):223-36.
1999: Ulrike Seitz; Bernd Neumaier; Gerhard Glatting; Jörg Kotzerke; Donald Bunjes; Sven N Reske
Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
European journal of nuclear medicine 1999;26(10):1265-73.
1999: Michael Schulte; D Brecht-Krauss; M Werner; Erich Hartwig; Michael R Sarkar; Peter Keppler; Jörg Kotzerke; Albrecht Guhlmann; G Delling; Sven N Reske
Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(10):1637-43.
1999: Holger Schirrmeister; Albrecht Guhlmann; K Elsner; Jörg Kotzerke; Gerhard Glatting; M Rentschler; Bernd Neumaier; H Träger; Karin Nüssle; Sven N Reske
Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(10):1623-9.
1999: F Moog; Jörg Kotzerke; Sven N Reske
FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(9):1407-13.
1999: Holger Schirrmeister; Albrecht Guhlmann; Jörg Kotzerke; C Santjohanser; Thorsten Kühn; R Kreienberg; PM Messer; Karin Nüssle; K Elsner; Gerhard Glatting; H Träger; Bernd Neumaier; CG Diederichs; Sven N Reske
Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2381-9.
1999: Michael Schulte; D Brecht-Krauss; B Heymer; Albrecht Guhlmann; Erich Hartwig; Michael R Sarkar; CG Diederichs; Markus Schultheiss; Jörg Kotzerke; Sven N Reske
Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible?
European journal of nuclear medicine 1999;26(6):599-605.
1999: Inga Buchmann; CA Guhlmann; K Elsner; W Gfrörer; Holger Schirrmeister; Jörg Kotzerke; Andreas Buck; Sven N Reske
[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].
Nuklearmedizin. Nuclear medicine 1999;38(8):319-22.
1999: Markus Bangerter; Jörg Kotzerke; Martin Griesshammer; K Elsner; Sven N Reske; Lothar Bergmann
Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest.
Acta oncologica (Stockholm, Sweden) 1999;38(6):799-804.
1999: Sabine Fenchel; Jörg Kotzerke; I Stöhr; Dieter Grab; Karin Nüssle; Andrea Rieber; Rolf Kreienberg; Hans-Juergen Brambs; Sven N Reske
[Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F 18 fluorodeoxyglucose].
Nuklearmedizin. Nuclear medicine 1999;38(4):101-7.
1999: Holger Schirrmeister; CA Guhlmann; K Elsner; Karin Nüssle; H Träger; Jörg Kotzerke; Sven N Reske
[Positron emission tomography of the skeletal system using 18FNa: frequency, distribution and appearance of skeletal metastases].
Röntgenpraxis; Zeitschrift für radiologische Technik 1999;52(1):19-25.
1999: Jörg Kotzerke; Albrecht Guhlmann; F Moog; Norbert Frickhofen; Sven N Reske
Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma.
European journal of nuclear medicine 1999;26(1):31-8.
1998: Albrecht Guhlmann; D Brecht-Krauss; Gebhard Suger; Gerhard Glatting; Jörg Kotzerke; Lothar Kinzl; Sven N Reske
Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1998;39(12):2145-52.
1998: Markus Bangerter; F Moog; Inga Buchmann; Jörg Kotzerke; Martin Griesshammer; M Hafner; K Elsner; Norbert Frickhofen; Sven N Reske; Lothar Bergmann
Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(10):1117-22.
1998: Holger Schirrmeister; Jörg Kotzerke; M Rentschler; H Träger; Sabine Fenchel; Karin Nüssle; CG Diederichs; Sven N Reske
[Positron-emission tomography of the skeletal system using 18FNa: the incidence, pattern of the findings and distribution of benign changes].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1998;169(3):310-4.
1998: Jörg Kotzerke; Sabine Fenchel; Albrecht Guhlmann; Michael Stabin; M Rentschler; Furn F Knapp; Sven N Reske
Pharmacokinetics of 99Tcm-pertechnetate and 188Re-perrhenate after oral administration of perchlorate: option for subsequent care after the use of liquid 188Re in a balloon catheter.
Nuclear medicine communications 1998;19(8):795-801.
1998: Holger Schirrmeister; M Rentschler; Jörg Kotzerke; CG Diederichs; Sven N Reske
[Imaging of the normal skeletal system with 18F Na-PET compared with conventional skeletal scintigraphy using Tc99m-MDP].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1998;168(5):451-6.
1998: Jörg Kotzerke; M Rentschler; Gerhard Glatting; E Schneider; Michael Stabin; Furn F Knapp; Sven N Reske
[Dosimetry fundamentals of endovascular therapy using Re-188 for the prevention of restenosis after angioplasty].
Nuklearmedizin. Nuclear medicine 1998;37(2):68-72.
1998: Albrecht Guhlmann; D Brecht-Krauss; Gebhard Suger; Gerhard Glatting; Jörg Kotzerke; Lothar Kinzl; Sven N Reske
Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings.
Radiology 1998;206(3):749-54.
1998: F Moog; Markus Bangerter; Jörg Kotzerke; Albrecht Guhlmann; Norbert Frickhofen; Sven N Reske
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(2):603-9.
1997: Jörg Kotzerke
[Principles of radio-synoviorthesis].
Röntgenpraxis; Zeitschrift für radiologische Technik 1997;50(6):150-4.
1997: F Moog; Markus Bangerter; CG Diederichs; Albrecht Guhlmann; Jörg Kotzerke; Elmar Merkle; O Kolokythas; F Herrmann; Sven N Reske
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Radiology 1997;203(3):795-800.
1997: Albrecht Guhlmann; Martin Storck; Jörg Kotzerke; F Moog; Ludger Sunder-Plassmann; Sven N Reske
Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).
Thorax 1997;52(5):438-41.
1997: Jörg Kotzerke; S Glatz; KG Grillenberger; Klaus Kleinschmidt; Sven N Reske
Reproducibility of a single-sample method for 99Tcm-MAG3 clearance under clinical conditions.
Nuclear medicine communications 1997;18(4):352-7.
1997: Jörg Kotzerke; K Bergmann; S Glatz; Martin Höher; Sven N Reske
[Whole body distribution of Tc-99m-sestamibi after pharmacological stress with arbutamine and dipyridamole compared with resting conditions].
Nuklearmedizin. Nuclear medicine 1997;36(1):19-22.
1996: S Glatz; Jörg Kotzerke; F Moog; M Sandherr; Hermann Heimpel; Sven N Reske
[Simulation of a mediastinal non-Hodgkin lymphoma recurrence by a diffuse thymus hyperplasia in 18F-FDG PET scan].
RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin 1996;165(3):309-10.